VivoSeq
Oncology

T-Cell Non-Hodgkin Lymphoma

44

Pipeline Programs↗

2

Active Trials↗

25

Companies Involved↗

T-cell non-Hodgkin lymphoma is a moderately active landscape with 44 programs across 25 companies. The most active players are Avyxa, Sanofi, BeiGene. 5 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

6/100

Mech. Concentration

12/100

Completion Rate

62/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

2 programs

Phase 1Sanofi logo

Sanofi

1 program

Phase 1BeiGene logo

BeiGene

1 program

Phase 1S

SymBio Pharmaceuticals

1 program

Phase 1E

Eastern Cooperative Oncology Group

3 programs

Phase 1Roche logo

Roche

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical6

Leucovorin Calcium

Eastern Cooperative Oncology Group

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Vincristine Sulfate

Eastern Cooperative Oncology Group

Mitoxantrone

EMD Serono

Azacitidine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 114

Mitoxantrone Hydrochloride

Pfizer

Pralatrexate

Acrotech Biopharma Inc.

Melphalan

Apotex Inc.

Cytarabine

Teva

Etoposide

Avyxa

Phase 219

Bexarotene

Bausch Health Americas, Inc.

Gemcitabine

Johnson & Johnson

Vorinostat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Rituximab

Roche

Bendamustine

Azurity Pharmaceuticals

Phase 3
No programs
Approved5

Romidepsin

Teva

Belinostat

Acrotech Biopharma Inc.

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Prednisone

Roxane Laboratories

Methotrexate

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

91%

Small molecule

39 of 43 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody37%Cell therapy12%

Small molecule leads; the ring shows all 43 classified programs, each share of the total. Modality classified for 100% of 45 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed8 · 53%
Terminated3 · 20%
Withdrawn2 · 13%
Recruiting1 · 7%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Recruiting·SSciTech Development, Inc.·Phase 1·NCT04234048·46 enrolled
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Not yet recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT07225985·50 enrolled
Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
Completed·UUniversity of Nebraska·Phase 2·NCT01431209·71 enrolled
Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
Completed·UUniversity College, London·Phase 2·NCT00660231·36 enrolled
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT01466881·42 enrolled
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Completed·WWake Forest University Health Sciences·Phase 1·NCT02168140·16 enrolled
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Completed·—·Phase 1·NCT01800838·11 enrolled
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
Completed·—·Phase 1·NCT02342782·20 enrolled
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01701986·64 enrolled
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Completed·UUniversity of Washington·Phase 1/2·NCT00601718·29 enrolled
RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00667017·1 enrolled
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
Terminated·FFox Chase Cancer Center·Phase 1/2·NCT02535247·17 enrolled
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
Terminated·WWake Forest University Health Sciences·Phase 2·NCT04217317·6 enrolled
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
Withdrawn·UUniversity of Miami·N/A·NCT00513188
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT04220008

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)